Elizabeth A Mullen1, Yueh-Yun Chi1, Emily Hibbitts1, James R Anderson1, Katarina J Steacy1, James I Geller1, Daniel M Green1, Geetika Khanna1, Marcio H Malogolowkin1, Paul E Grundy1, Conrad V Fernandez1, Jeffrey S Dome1. 1. Elizabeth A. Mullen, Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center, Boston, MA; Yueh-Yun Chi and Emily Hibbitts, University of Florida, Gainesville, FL; James R. Anderson, Merck Research Laboratories, North Wales, PA; Katarina J. Steacy, University of Maryland Medical Center, Baltimore, MD; James I. Geller, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Daniel M. Green, St Jude Children's Research Hospital, Memphis, TN; Geetika Khanna, Washington University School of Medicine, St Louis, MO; Marcio H. Malogolowkin, University of California at Davis Comprehensive Cancer Center, Sacramento, CA; Paul E. Grundy, Stollery Children's Hospital, University of Alberta, Alberta; Conrad V. Fernandez, IWK Health Center, Dalhousie University Halifax, Nova Scotia, Canada; and Jeffrey S. Dome, Children's National Health System, George Washington University School of Medicine and Health Sciences, Washington, DC.
Abstract
PURPOSE: The use of computed tomography (CT) for routine surveillance to detect recurrence in patients with Wilms tumor (WT) has increased in recent years. The utility of CT, despite increased risk and cost, to improve outcome for these patients is unknown. We conducted a retrospective analysis with patients enrolled in the fifth National Wilms Tumor Study (NWTS-5) to determine if surveillance with CT correlates with improved overall survival (OS) after recurrence compared with chest x-ray (CXR) and abdominal ultrasound (US). PATIENTS AND METHODS: Overall, 281 patients with recurrent unilateral favorable-histology WT were reviewed to assess how WT recurrence was detected: sign/symptoms (SS), surveillance imaging (SI) with CT scan, or SI with CXR/US. RESULTS: The estimated 5-year OS rate after relapse was 67% (95% CI, 61% to 72%). Twenty-five percent of recurrences were detected with SS; 48.5%, with CXR/US; and 26.5%, with CT. Patients with SS had a 5-year OS rate of 59% (95% CI, 46% to 72%) compared with 70% (95% CI, 63% to 77%; P = .23) for those detected by SI. Recurrences detected by CT had a shorter median time from diagnosis to recurrence (0.60 years) compared with SS (0.91 years) or CXR/US (0.86 years; P = .003). For recurrences detected by SI, more tumor foci at relapse ( P < .001) and size of the largest focus greater than 2 cm ( P = .02) were associated with inferior OS. However, there was no difference in OS after relapse when recurrence was detected by CT versus CXR/US (5-year OS rate, 65% v 73%; P = .20). CONCLUSION: In patients with favorable-histology WT, elimination of CT scans from surveillance programs is unlikely to compromise survival but would result in substantial reduction in radiation exposure and health care costs.
PURPOSE: The use of computed tomography (CT) for routine surveillance to detect recurrence in patients with Wilms tumor (WT) has increased in recent years. The utility of CT, despite increased risk and cost, to improve outcome for these patients is unknown. We conducted a retrospective analysis with patients enrolled in the fifth National Wilms Tumor Study (NWTS-5) to determine if surveillance with CT correlates with improved overall survival (OS) after recurrence compared with chest x-ray (CXR) and abdominal ultrasound (US). PATIENTS AND METHODS: Overall, 281 patients with recurrent unilateral favorable-histology WT were reviewed to assess how WT recurrence was detected: sign/symptoms (SS), surveillance imaging (SI) with CT scan, or SI with CXR/US. RESULTS: The estimated 5-year OS rate after relapse was 67% (95% CI, 61% to 72%). Twenty-five percent of recurrences were detected with SS; 48.5%, with CXR/US; and 26.5%, with CT. Patients with SS had a 5-year OS rate of 59% (95% CI, 46% to 72%) compared with 70% (95% CI, 63% to 77%; P = .23) for those detected by SI. Recurrences detected by CT had a shorter median time from diagnosis to recurrence (0.60 years) compared with SS (0.91 years) or CXR/US (0.86 years; P = .003). For recurrences detected by SI, more tumor foci at relapse ( P < .001) and size of the largest focus greater than 2 cm ( P = .02) were associated with inferior OS. However, there was no difference in OS after relapse when recurrence was detected by CT versus CXR/US (5-year OS rate, 65% v 73%; P = .20). CONCLUSION: In patients with favorable-histology WT, elimination of CT scans from surveillance programs is unlikely to compromise survival but would result in substantial reduction in radiation exposure and health care costs.
Authors: David B Dix; Nita L Seibel; Yueh-Yun Chi; Geetika Khanna; Eric Gratias; James R Anderson; Elizabeth A Mullen; James I Geller; John A Kalapurakal; Arnold C Paulino; Elizabeth J Perlman; Peter F Ehrlich; Marcio Malogolowkin; Julie M Gastier-Foster; Elizabeth Wagner; Paul E Grundy; Conrad V Fernandez; Jeffrey S Dome Journal: J Clin Oncol Date: 2018-04-16 Impact factor: 44.544
Authors: Danqing Hu; Randall P Flick; Michael J Zaccariello; Robert C Colligan; Slavica K Katusic; Darrell R Schroeder; Andrew C Hanson; Shonie L Buenvenida; Stephen J Gleich; Robert T Wilder; Juraj Sprung; David O Warner Journal: Anesthesiology Date: 2017-08 Impact factor: 7.892
Authors: C F Torres; S Rebsamen; J H Silber; L N Sutton; L T Bilaniuk; R A Zimmerman; J W Goldwein; P C Phillips; B J Lange Journal: N Engl J Med Date: 1994-03-31 Impact factor: 91.245
Authors: Marilyn J Goske; Keith J Strauss; Laura P Coombs; Keith E Mandel; Alexander J Towbin; David B Larson; Michael J Callahan; Kassa Darge; Daniel J Podberesky; Donald P Frush; Sjirk J Westra; Jeffrey S Prince Journal: Radiology Date: 2013-03-19 Impact factor: 11.105
Authors: H M Eissa; C E Allen; K Kamdar; S Simko; P Goradia; Z Dreyer; P Steuber; K L McClain; R P Guillerman; Catherine M Bollard Journal: Pediatr Hematol Oncol Date: 2013-10-02 Impact factor: 1.969
Authors: Corinne Daly; David R Urbach; Thérèse A Stukel; Paul C Nathan; Wayne Deitel; Lawrence F Paszat; Andrew S Wilton; Nancy N Baxter Journal: BMC Cancer Date: 2015-09-03 Impact factor: 4.430
Authors: Maja Stanojevic; Amy B Hont; Ashley Geiger; Samuel O'Brien; Robert Ulrey; Melanie Grant; Anushree Datar; Ping-Hsien Lee; Haili Lang; Conrad R Y Cruz; Patrick J Hanley; A John Barrett; Michael D Keller; Catherine M Bollard Journal: Cytotherapy Date: 2021-04-05 Impact factor: 6.196
Authors: Laura M Madanat-Harjuoja; Lindsay A Renfro; Kelly Klega; Brett Tornwall; Aaron R Thorner; Anwesha Nag; David Dix; Jeffrey S Dome; Lisa R Diller; Conrad V Fernandez; Elizabeth A Mullen; Brian D Crompton Journal: J Clin Oncol Date: 2022-05-17 Impact factor: 50.717
Authors: Ryan Thibodeau; Abtin Jafroodifar; Marlon Coelho; Hsin Kwung Li; Lorenzo Gitto; Daniel J Zaccarini; Mary McGrath Journal: Radiol Case Rep Date: 2021-06-08